A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid.
about
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronanCD44 cell adhesion moleculesHyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growthKunitz-type protease inhibitor bikunin disrupts phorbol ester-induced oligomerization of CD44 variant isoforms containing epitope v9 and subsequently suppresses expression of urokinase-type plasminogen activator in human chondrosarcoma cellsHomodimerization of the Lymph Vessel Endothelial Receptor LYVE-1 through a Redox-labile Disulfide Is Critical for Hyaluronan Binding in Lymphatic EndotheliumSignal transduction via CD44: role of plasma membrane microdomains.CD44 Promotes intoxication by the clostridial iota-family toxinsAcylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosisIdentification of a costimulatory molecule rapidly induced by CD40L as CD44H.CD44 engagement promotes matrix-derived survival through the CD44-SRC-integrin axis in lipid raftsCell-surface prion protein interacts with glycosaminoglycansHyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells.IL-6 regulates CD44 cell surface expression on human myeloma cells.CD44 signaling through p56lck involves lateral association with CD4 in human CD4+ T cells.Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation.Chimeric CD4/CD44 molecules associate with CD44 via the transmembrane region and reduce hyaluronan binding in T cell lines.Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein.A requirement for the CD44 cytoplasmic domain for hyaluronan binding, pericellular matrix assembly, and receptor-mediated endocytosis in COS-7 cells.Role of the extracellular and cytoplasmic domains of CD44 in the rolling interaction of lymphoid cells with hyaluronan under physiologic flow.Coming of Age: CD96 Emerges as Modulator of Immune Responses.
P2860
Q22008808-F23D8640-D872-4AEB-A975-D9DACB9BCA15Q24568164-E997D194-E6E8-40C6-B3BE-C9150CC620CEQ28199263-4D9CD0E0-B7BA-489D-B76E-63AE7B010EE5Q28214558-F3C7C586-7EA5-4C3B-A1D3-EB89AAE31575Q28593262-9EA5DC41-3561-43E5-8B3C-97769B009C69Q33803238-B91B22D1-CF15-4D13-B13B-366B1E9EE027Q34510922-A33A33CA-FA5D-45B3-B32C-94540BE95DE4Q34577980-418E7A28-4C1C-44A8-86AE-F03B0F988F8DQ36367256-5D9F2431-9D8E-44BE-B3B1-80A428EF0D0EQ36898765-CD20AD05-AE74-4B4F-A5CC-3BC71727023BQ38363614-226716CE-62E1-47EE-BF9B-4D89CC11B7C3Q40579310-3F05E474-6966-4440-B333-D570DE0B857EQ40579834-D7C5BEB5-AB16-40DC-B37A-F36ACDEC04F4Q40945553-A3845AFC-EE8C-4633-94D8-BE8B9E9646F9Q41083579-3898461D-EEAB-466A-BD5F-0021D7D22092Q42828789-6DBC92FA-8165-4D5B-8426-B1A44F28BDDFQ43559228-9B8B42AC-3A52-4ACB-94DC-62E002412B7BQ43855729-0343F271-6BEF-4B67-818A-CC912E5FCC64Q44286571-1C72D3B3-EE79-4A26-8B76-E2470097E031Q55026846-B8E567AE-D417-447F-91E8-398E47CFB8EA
P2860
A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
A cysteine residue located in ...... ng of CD44 to hyaluronic acid.
@ast
A cysteine residue located in ...... ng of CD44 to hyaluronic acid.
@en
type
label
A cysteine residue located in ...... ng of CD44 to hyaluronic acid.
@ast
A cysteine residue located in ...... ng of CD44 to hyaluronic acid.
@en
prefLabel
A cysteine residue located in ...... ng of CD44 to hyaluronic acid.
@ast
A cysteine residue located in ...... ng of CD44 to hyaluronic acid.
@en
P2860
P356
P1476
A cysteine residue located in ...... ng of CD44 to hyaluronic acid.
@en
P2860
P304
P356
10.1084/JEM.183.5.1987
P407
P577
1996-05-01T00:00:00Z